Clinical Trials Logo

Filter by:
NCT ID: NCT00373776 Completed - Leishmaniasis Clinical Trials

Miltefosine for Mucosal Leishmaniasis

Start date: April 2004
Phase: Phase 1/Phase 2
Study type: Interventional

This trial will study miltefosine as a treatment for mucosal leishmaniasis.

NCT ID: NCT00373568 Completed - Leishmaniasis Clinical Trials

Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis

Start date: April 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis

NCT ID: NCT00233545 Completed - Clinical trials for Cutaneous Leishmaniasis

Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia

Start date: September 2005
Phase: Phase 2
Study type: Interventional

Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony. Standard dose regimens will be used for both drugs.

NCT ID: NCT00216333 Recruiting - Tuberculosis Clinical Trials

Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis

Start date: December 2003
Phase: Phase 4
Study type: Interventional

The use of fixed-dose combined (FDC) drugs in the treatment of tuberculosis by National Tuberculosis Programmes has been recommended by both the International Union Against Tuberculosis and Lung Disease (The Union) and the World Health Organisation. The advantages of FDC drugs include preventing the emergence of drug resistance due to monotherapy, reducing the risk of incorrect dosage, simplifying procurement and prescribing practices, aiding adherence and facilitating directly observed treatment. Recent bioavailability studies of four-drug FDC tablets have demonstrated satisfactory results. In this study, we are testing the efficacy of this compound, when given in the initial intensive phase of treatment of patients with newly diagnosed smear positive pulmonary tuberculosis. This will be followed by four months treatment with a two-drug FDC of rifampicin and isoniazid.

NCT ID: NCT00123916 Completed - Heart Disease Clinical Trials

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

BENEFIT
Start date: November 2004
Phase: Phase 3
Study type: Interventional

Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.